Bio-Techne (TECH) announced an expansion of the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics, or ACD, and Leica Biosystems, a global leader in anatomic pathology solutions. The expanded spatial multiomic collaboration now includes automation of ACD’s new RNAscope Multiomic LS Assay and protease-free workflows on Leica’s BOND RX research staining instrument, further advancing the capabilities of spatial biology research. The RNAscope Multiomic LS Assay enables simultaneous fluorescent detection of up to six RNA and/or protein biomarkers on the same slide, preserving RNA and protein integrity while maintaining tissue morphology. Additionally, ACD introduced a protease-free workflow for RNAscope 2.5 single-plex assays on the Leica BOND RX staining instrument, further advancing multiomic visualization from discovery research to translational applications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne highlights advances in detection of biomarkers using RNAscope
- Coinbase initiated, Block upgraded: Wall Street’s top analyst calls
- Bio-Techne initiated with an Outperform at Evercore ISI
- Bio-Techne: A Premium Growth Asset with Strong Market Position and Promising Future
- Bio-Techne named short-term buy idea at Deutsche Bank